Overview
Curis Q3 revenue increased year-over-year, beating analysts' expectations of a decline
Net loss for Q3 narrowed to $7.13 mln from $10.1 mln
Company continues advancing clinical studies in PCNSL, CLL, and AML
Outlook
Curis expects to enroll first CLL patient in late Q4 2025 or early Q1 2026
Company anticipates cash runway into Q1 2026
Result Drivers
ROYALTY REVENUE - Revenue rose to $3.2 mln from $2.9 mln, consisting of royalty revenues from Genentech/Roche's sales of Erivedge
R&D EXPENSES - Declined to $6.4 mln from $9.7 mln due to lower clinical, employee related, manufacturing, research, and consulting costs
Key Details
Metric | Beat/Miss | Actual | Consensus Estimate |
Q3 Revenue | Beat | $3.18 mln | $2.86 mln (5 Analysts) |
Q3 Net Income | Beat | -$7.73 mln | -$8.22 mln (5 Analysts) |
Q3 Basic EPS | Beat | -$0.49 | -$0.58 (5 Analysts) |
Q3 Income From Operations | Beat | -$6.92 mln | -$8.20 mln (4 Analysts) |
Analyst Coverage
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 5 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"
The average consensus recommendation for the biotechnology & medical research peer group is "buy"
Wall Street's median 12-month price target for Curis Inc is $17.00, about 91.6% above its November 5 closing price of $1.42
Press Release: ID:nPn2cV58Xa
For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.
(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)